Company Overview and News


Add GNFT
to your dashboard

Headline News

Notable BioSci Mover - October 6, 2017 Report

2017-12-07 seekingalpha
Shares of Madrigal Pharmaceuticals catapulted to new high due to robust phase 2 data reporting for NASH. (99-1)

Liver Fibrosis Therapeutic Development and Pipeline Review H1 2017 Research Report Now Available at RnRMarketResearch

2017-05-23 prnewswire
RnRMarketResearch.com adds "Liver Fibrosis - Pipeline Review, H1 2017" therapeutic market research report of 200 pages with latest updates, data and information to its online business intelligence library. (0-2)

2 Possible Acquisition Targets For Gilead Sciences

2017-01-27 seekingalpha
M&A activity is seeing a noticeable uptick to start the year compared to a punk 2016 for transactions. (0-1)

Allergan to buy Tobira in push for NASH treatments

2016-09-20 channelnewsasia
REUTERS: Allergan Plc said it would buy Tobira Therapeutics Inc in a deal worth up to US$1.7 billion, about 19 times the company's current value, to get a leg up in the race to develop therapies for NASH, an incurable fatty liver disease. (0-1)

Can-Fite Unveils New Indication To Treat NASH The Next Big Global Epidemic

2016-09-19 seekingalpha
The term 'platform technology' gets a lot of play, some of it hype, but when an emerging and scientifically sound biotech company shows promise of multiple uses for its core drug, investors should take notice. This is the case with Can-Fite BioPharma Ltd. (NYSEMKT:CANF), who last month released convincing preclinical data that its CF102, currently in trials for a common form of liver cancer, has a beneficial effect on non-alcoholic steatohepatitis (NYSEARCA:NASH), an insidious disease not readily manifested, making it all the more dangerous.

Pipeline Insights on Nonalcoholic Steatohepatitis Market

2016-09-12 prnewswire
RnRMarketResearch.com adds "Non-Alcoholic Steatohepatitis - Pipeline Review, H2 2016" market research report with comprehensive information on NASH therapeutic development complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases.

NASH Market (Drugs) to see 25.56% CAGR During 2020 - 2030

2016-05-06 prnewswire
Global NASH market report says progressive numbers of liver disorders along with rise in obesity will fuel the demand for NASH (non-alcoholic steatohepatitis) drugs in the coming few years. The NASH Market is growing at a moderate rate over last five years on account of rising number of obesity among young population. NASH (non-alcoholic steatohepatitis) is a large, un-tapped market with no FDA approved therapeutics.

Nonalcoholic Steatohepatitis (NASH) Therapeutics Market to Reach US$20.27 bn by 2025, Elafibranor Projected to Spur Growth: Transparency Market Research

2016-04-18 prnewswire
According to a new market report published by Transparency Market Research "Nonalcoholic Steatohepatitis Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2015 - 2025", the nonalcoholic steatohepatitis (NASH) therapeutics market is anticipated to expand at a CAGR of 10.7% from 2015 to 2025 to reach US$20.27 bn by 2025. (0-1)

Genfit plans to test its drug in second liver disease

2016-03-31 channelnewsasia
NEW YORK: French drugmaker Genfit SA on Thursday said it would begin a midstage trial this year of its experimental drug elafibranor to treat primary biliary cholangitis, a chronic disease in which bile ducts in the liver are gradually destroyed. (0-1)